Compounded Topical Tofacitinib: What Prescribers Should Know
Tofacitinib is FDA approved as an oral tablet and carries a boxed warning. No topical tofacitinib product is approved anywhere. And the one topical JAK inhibitor FDA has approved carries the same boxed warning as the oral drugs, which settles the question of whether the topical route avoids it.
What topical tofacitinib is
Tofacitinib is a Janus kinase inhibitor, blocking JAK1 and JAK3 signaling and interrupting the cytokine pathways that drive several inflammatory and autoimmune conditions. It is FDA approved in the United States as an oral tablet for rheumatologic and gastrointestinal indications.
A compounded topical preparation puts that same active into a cream, gel or solution applied to skin or scalp. It is made individually by a pharmacy to the concentration a prescriber specifies, under a valid prescription.
Dermatologic use of tofacitinib in any form is off label, and the topical route is unapproved on top of that.
The reasoning behind the topical route
The intent is to deliver drug to affected skin while keeping the amount reaching the rest of the body low. For a class of drugs whose systemic warnings are the main obstacle to using them, that reasoning is easy to follow.
Studies of topical JAK inhibitors have generally reported low systemic concentrations after application. In an early psoriasis study of topical ruxolitinib, no significant inhibition of the relevant signaling was observed in peripheral blood cells, consistent with the low plasma levels measured.
Low systemic exposure is a measurable finding. It is not the same as an absence of systemic exposure, and as the next section shows, FDA did not treat it as one when it approved a topical JAK inhibitor.
The boxed warning follows the drug, not the route
Topical ruxolitinib cream, the only FDA approved topical JAK inhibitor in the United States, carries boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. These are the same boxed warnings that appear on the oral JAK inhibitors.
Reviews note that the incidence of these events was low in the topical trials. FDA nonetheless applied the class boxed warning to a cream, which is the clearest available answer to whether topical application removes the warning. It does not.
A compounded topical tofacitinib preparation has no FDA reviewed labeling at all, so it carries no boxed warning of its own. That is an absence of review rather than an absence of risk, and it is a meaningful distinction to raise with a patient.
What is FDA approved instead
Approved options exist for most of the conditions topical tofacitinib is compounded for, and where an approved product fits the patient it is generally the appropriate first choice.
| Condition | Approved JAK option | Route |
|---|---|---|
| Nonsegmental vitiligo | Ruxolitinib cream, approved July 2022 for patients aged 12 and over | Topical |
| Mild to moderate atopic dermatitis | Ruxolitinib cream, approved September 2021 for patients aged 12 and over | Topical |
| Severe alopecia areata | Oral JAK inhibitors including baricitinib and ritlecitinib | Oral |
| Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis | Tofacitinib itself, as an oral tablet | Oral |
Compounding earns its place when something specific does not fit, such as a concentration or vehicle no manufactured product offers, a site the approved cream is not indicated for, or a reaction to an ingredient in the commercial product.
What the evidence shows
The published evidence for topical tofacitinib consists mainly of case reports, case series and small pilot studies. There is no large randomized trial of a compounded topical tofacitinib preparation.
Reported uses in the literature include alopecia areata in adults and children, lichen planopilaris, psoriasis and atopic dermatitis. A double blind pilot study of topical JAK inhibitors in alopecia universalis is among the small number of controlled reports available.
By contrast, topical ruxolitinib has been tested in identical phase III vehicle controlled trials in vitiligo, where the primary facial repigmentation endpoint was reached by roughly 30 percent of cream recipients against 7 to 11 percent on vehicle. That is the difference in evidence quality between an approved product and a compounded one.
Why alopecia areata is the harder case
Alopecia areata is the use topical JAK inhibitors are most often sought for, and it is where the evidence is weakest. Reviews of topical JAK inhibitors describe the alopecia areata results as conflicting, with no consistent findings established.
The suspected reason is anatomical. The inflammatory target in alopecia areata sits deep around the hair follicle, and a topically applied drug has to reach it. Oral JAK inhibitors, which reach the follicle through the bloodstream, have produced far stronger results and are the ones that gained approval for the condition.
None of this means a prescriber cannot reasonably try a topical preparation in a particular patient. It means the conversation should be honest about what has and has not been shown.
Question about a concentration, a vehicle, or whether an active suits a particular site?
Call (909) 378-7301Dosage forms and concentrations
Topical tofacitinib is compounded as a cream, ointment, gel or solution, with the form chosen to suit the site of application. Published reports have generally used 2 percent preparations, which describes the literature rather than a recommendation.
| Form | Typical site | Why a prescriber picks it |
|---|---|---|
| Cream | Body and face | Familiar feel, spreads over a broad area, suits most skin types |
| Ointment | Dry or fissured skin | Occlusive finish, often used where hydration matters |
| Gel | Face and hair bearing areas | Lighter finish, absorbs quickly, less residue |
| Solution | Scalp | Reaches the scalp through hair without a greasy residue |
The vehicle matters as much as the form, since it governs how the active moves into skin and how stable the preparation stays through its beyond use date. Name a preference on the prescription or write pharmacist's choice.
Side effects and cautions
JAK inhibitor labeling in the United States carries boxed warnings for serious and sometimes fatal infections, increased mortality, malignancy including lymphoma, major adverse cardiovascular events, and thrombosis. These warnings appear on the approved topical JAK inhibitor as well as the oral products. A prescriber assesses individual risk before starting any JAK inhibitor and discusses infection risk, cardiovascular and clotting history, malignancy history and smoking status. Report fever, unusual infection, chest pain, shortness of breath, or leg swelling promptly. This is not a complete account of the labeling.
Application site reactions are the most commonly reported local effects with topical JAK inhibitors, including acne, itching and skin peeling in the approved product's trials. Because a compounded preparation has no FDA reviewed labeling, there is no established maximum treated body surface area, no defined maximum duration, and no complete adverse effect profile for that specific preparation. Tell your prescriber about pregnancy or the possibility of pregnancy, breastfeeding, any history of infection, cancer or blood clots, and every medication you take, before starting.
Sending a prescription to Mixwell
State the concentration as a percentage, the dosage form, the total quantity and the directions including the application site. Call first if you want to discuss vehicle selection for a particular site.
- Write the concentration as a percentage and specify cream, ointment, gel or solution.
- State the total quantity in grams or millilitres and the directions including the site and frequency.
- Note the vehicle preference or write pharmacist's choice, and list any additional actives.
- Call (909) 378-7301 to confirm the formulation and current turnaround time.
Serving prescribers and patients in California
Mixwell Compounding Pharmacy is located in Chino, CA and works with dermatology and primary care prescribers across the Inland Empire, Los Angeles County and Orange County. Patients can collect their preparation at the Chino pharmacy, and delivery is available across California.
- Chino
- Chino Hills
- Ontario
- Rancho Cucamonga
- Upland
- Pomona
- Diamond Bar
- Corona
- Riverside
- Eastvale
- Brea
- Fullerton
Common questions
Is topical tofacitinib FDA approved?
No. Tofacitinib is FDA approved in the United States as an oral tablet for rheumatologic and gastrointestinal indications. There is no FDA approved topical tofacitinib product, and dermatologic use is off label. A compounded topical is prepared individually under a valid prescription.
Does the topical route avoid the JAK inhibitor boxed warning?
No. Topical ruxolitinib cream, the only FDA approved topical JAK inhibitor in the United States, carries the same boxed warnings as the oral JAK inhibitors, covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. FDA applied the class warning to a topical product.
Is there an approved topical JAK inhibitor?
Yes. Ruxolitinib cream is approved for mild to moderate atopic dermatitis and for nonsegmental vitiligo in patients aged 12 and over. Where an approved product fits the patient, it is generally the appropriate first choice.
Does topical tofacitinib work for alopecia areata?
The evidence is limited and conflicting. Reviews of topical JAK inhibitors report no consistent findings in alopecia areata, likely because the inflammatory target sits deep around the hair follicle. Oral JAK inhibitors have produced stronger results and are the ones approved for the condition.
What concentrations are used?
Published reports of topical tofacitinib have generally used 2 percent preparations. That describes the literature rather than a recommendation, and the appropriate concentration for any patient is a decision for the prescriber.
Should I talk to my prescriber first?
Yes. FDA recommends that patients talk with their health care professional about their specific circumstances before taking any medication, including compounded preparations. That applies with particular force to a drug class carrying boxed warnings.
Does Mixwell accept insurance?
Mixwell does not accept insurance. Call (909) 378-7301 to discuss current pricing.
Key Takeaways
- Tofacitinib is FDA approved only as an oral tablet in the United States, and no topical tofacitinib product is approved.
- The approved topical JAK inhibitor carries the same boxed warnings as the oral drugs, so the topical route does not remove the class warning.
- Approved options exist for most conditions topical tofacitinib is compounded for, including ruxolitinib cream for vitiligo and atopic dermatitis and oral JAK inhibitors for severe alopecia areata.
- Evidence for topical tofacitinib is limited to case reports, case series and small pilot studies, and is specifically conflicting in alopecia areata.
- Compounded preparations are not FDA approved, have no reviewed labeling, and require a valid prescription from a licensed prescriber.
Sources
- Ruxolitinib cream 1.5%: a review in non-segmental vitiligo. Drugs. 2024. PMC11189965
- Spadafora M, et al. Off-label use of topical ruxolitinib in dermatology: a systematic literature review and current perspectives. Experimental Dermatology. 2025. doi:10.1111/exd.70095
- Utilization of topical ruxolitinib in dermatology: a review. Skin Therapy Letter. 2023.
- Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors: a double blind, placebo and active controlled pilot study. International Journal of Dermatology. 2018;57:1464-1470.
- Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. Journal of the American Academy of Dermatology. 2017;77:167-170.
- U.S. Food and Drug Administration. Tofacitinib and ruxolitinib cream prescribing information, including boxed warnings.
- U.S. Food and Drug Administration. Compounding and the FD&C Act, Section 503A.